Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Pronk LM"'
Publikováno v:
In Value in Health December 2022 25(12) Supplement:S308-S308
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Rohaan MW; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Gomez-Eerland R; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Berg JH; Biotherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., Geukes Foppen MH; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Zon M; Biotherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., Raud B; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Jedema I; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Scheij S; Biotherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Boer R; Biotherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., Bakker NAM; Biotherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Broek D; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands., Pronk LM; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Grijpink-Ongering LG; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Sari A; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Kessels R; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Haak M; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Mallo HA; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Karger M; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van de Wiel BA; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Zuur CL; Department of Head and Neck Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands., Duinkerken CW; Department of Head and Neck Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands., Lalezari F; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Thienen JV; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Wilgenhof S; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Blank CU; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Beijnen JH; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Nuijen B; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Schumacher TN; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Publikováno v:
Immuno-oncology technology [Immunooncol Technol] 2022 Jun 18; Vol. 15, pp. 100089. Date of Electronic Publication: 2022 Jun 18 (Print Publication: 2022).
Autor:
Verhaart SL; Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, London, United Kingdom., Abu-Ghanem Y; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., Mulder SF; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Oosting S; Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands., Van Der Veldt A; Department of Medical Oncology, Erasmus Medical Center-Cancer Institute, Rotterdam, The Netherlands., Osanto S; Department of Medical Oncology, Leids University Medical Center, Leiden, The Netherlands., Aarts MJB; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands., Houtsma D; Department of Medical Oncology, HAGA Hospital, The Hague, The Netherlands., Peters FPJ; Department of Medical Oncology, Zuyderland Hospital, Sittard - Geleen, The Netherlands., Groenewegen G; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Pronk LM; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Tascilar M; Department of Medical Oncology, Isala Clinics, Zwolle, The Netherlands., Hamberg P; Department of Medical Oncology, Franciscus Gasthuis and Vllietland, Rotterdam, The Netherlands., Los M; Department of Medical Oncology, St. Antonius Hospital, Nieuwegein, The Netherlands., Vreugdenhil G; Department of Medical Oncology, Máxima Medical Center, Eindhoven, The Netherlands., Polee M; Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden, The Netherlands., Ten Tije AJ; Department of Medical Oncology, Amphia Hospital, Breda, The Netherlands., Haanen JBAG; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Bex A; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands; Division of Surgery and Interventional Science, University College London, London, United Kingdom; Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: axel.bex@nhs.net., van den Eertwegh AJ; Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, London, United Kingdom.
Publikováno v:
Clinical genitourinary cancer [Clin Genitourin Cancer] 2021 Jun; Vol. 19 (3), pp. 274.e1-274.e16. Date of Electronic Publication: 2020 Oct 14.
Autor:
van den Berg JH; BioTherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., Heemskerk B; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Rooij N; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Gomez-Eerland R; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Michels S; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Zon M; BioTherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Boer R; BioTherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., Bakker NAM; BioTherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., Jorritsma-Smit A; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Buuren MM; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Kvistborg P; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Spits H; AIMM Therapeutics, Amsterdam, The Netherlands.; Experimental Immunology, Amsterdam University Medical Centres, Amsterdam, Noord-Holland, The Netherlands., Schotte R; AIMM Therapeutics, Amsterdam, The Netherlands., Mallo H; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Karger M; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Hage JA; Department of Surgery, Leiden Universitair Medisch Centrum, Leiden, Zuid-Holland, The Netherlands., Wouters MWJM; Surgical Oncology, Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, The Netherlands.; Dutch Institute for Clinical Auditing, Leiden, The Netherlands., Pronk LM; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Geukes Foppen MH; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Blank CU; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, The Netherlands., Beijnen JH; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University Department of Pharmaceutical Sciences, Utrecht, Utrecht, The Netherlands., Nuijen B; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Schumacher TN; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Haanen JBAG; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands j.haanen@nki.nl.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Aug; Vol. 8 (2).
Autor:
Rozeman EA; The Netherlands Cancer Institute, Amsterdam, Netherlands., Menzies AM; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., van Akkooi ACJ; The Netherlands Cancer Institute, Amsterdam, Netherlands., Adhikari C; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia., Bierman C; The Netherlands Cancer Institute, Amsterdam, Netherlands., van de Wiel BA; The Netherlands Cancer Institute, Amsterdam, Netherlands., Scolyer RA; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia., Krijgsman O; The Netherlands Cancer Institute, Amsterdam, Netherlands., Sikorska K; The Netherlands Cancer Institute, Amsterdam, Netherlands., Eriksson H; Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden., Broeks A; The Netherlands Cancer Institute, Amsterdam, Netherlands., van Thienen JV; The Netherlands Cancer Institute, Amsterdam, Netherlands., Guminski AD; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., Acosta AT; The Netherlands Cancer Institute, Amsterdam, Netherlands., Ter Meulen S; The Netherlands Cancer Institute, Amsterdam, Netherlands., Koenen AM; The Netherlands Cancer Institute, Amsterdam, Netherlands., Bosch LJW; The Netherlands Cancer Institute, Amsterdam, Netherlands., Shannon K; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia., Pronk LM; The Netherlands Cancer Institute, Amsterdam, Netherlands., Gonzalez M; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia., Ch'ng S; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia., Grijpink-Ongering LG; The Netherlands Cancer Institute, Amsterdam, Netherlands., Stretch J; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia., Heijmink S; The Netherlands Cancer Institute, Amsterdam, Netherlands., van Tinteren H; The Netherlands Cancer Institute, Amsterdam, Netherlands., Haanen JBAG; The Netherlands Cancer Institute, Amsterdam, Netherlands., Nieweg OE; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia., Klop WMC; The Netherlands Cancer Institute, Amsterdam, Netherlands., Zuur CL; The Netherlands Cancer Institute, Amsterdam, Netherlands., Saw RPM; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia., van Houdt WJ; The Netherlands Cancer Institute, Amsterdam, Netherlands., Peeper DS; The Netherlands Cancer Institute, Amsterdam, Netherlands., Spillane AJ; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., Hansson J; Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden., Schumacher TN; The Netherlands Cancer Institute, Amsterdam, Netherlands., Long GV; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia., Blank CU; The Netherlands Cancer Institute, Amsterdam, Netherlands. Electronic address: c.blank@nki.nl.
Publikováno v:
The Lancet. Oncology [Lancet Oncol] 2019 Jul; Vol. 20 (7), pp. 948-960. Date of Electronic Publication: 2019 May 31.
Autor:
Blank CU; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands. c.blank@nki.nl.; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. c.blank@nki.nl., Rozeman EA; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Fanchi LF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Sikorska K; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., van de Wiel B; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Kvistborg P; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Krijgsman O; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Braber M; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Philips D; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Broeks A; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Thienen JV; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Mallo HA; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Adriaansz S; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Ter Meulen S; Surgical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Pronk LM; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Grijpink-Ongering LG; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Bruining A; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Gittelman RM; Adaptive Biotechnologies, Seattle, WA, USA., Warren S; NanoString Technologies, Inc., Seattle, WA, USA., van Tinteren H; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Peeper DS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Haanen JBAG; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Akkooi ACJ; Surgical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Schumacher TN; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. t.schumacher@nki.nl.
Publikováno v:
Nature medicine [Nat Med] 2018 Nov; Vol. 24 (11), pp. 1655-1661. Date of Electronic Publication: 2018 Oct 08.
Autor:
Biró E; Department of Clinical Chemistry, F-1-219, Academic Medical Center, University of Amsterdam, PO Box 22660, 1100 DD, Amsterdam, Netherlands. E.Biro@amc.nl, Nieuwland R, Tak PP, Pronk LM, Schaap MC, Sturk A, Hack CE
Publikováno v:
Annals of the rheumatic diseases [Ann Rheum Dis] 2007 Aug; Vol. 66 (8), pp. 1085-92. Date of Electronic Publication: 2007 Jan 29.